Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15461612 | 0.89 | PDE4D (0.39) | GRM5KDM4E | |
| SCHEMBL233588 | 0.83 | HAO1 (0.37) | — | |
| SCHEMBL233144 | 0.82 | HAO1 (0.38) | — | |
| SCHEMBL233546 | 0.82 | HAO1 (0.38) | — | |
| SCHEMBL235715 | 0.82 | HAO1 (0.38) | — | |
| SCHEMBL14576175 | 0.82 | GRM5 (0.32) | GRM5 | |
| SCHEMBL23491278 | 0.81 | ACACB (0.31) | — | |
| SCHEMBL235958 | 0.80 | PTGES (0.38) | — | |
| SCHEMBL16031974 | 0.80 | HAO1 (0.40) | GRM5 | |
| SCHEMBL238038 | 0.80 | DDB1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795136-B2 | Methods for the treatment of diabetic retinopathy and other ophthalmic diseases | ACUCELA INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20210171435-A1 | Methods for the Treatment of Diabetic Retinopathy and other Ophthalmic Diseases | ACUCELA INC. | 2021-06-10 | — | — | US | disclosed |
| US-10730825-B2 | Methods for the treatment of diabetic retinopathy and other ophthalmic diseases | ACUCELA INC. (US) | 2020-08-04 | — | — | US | disclosed |
| EP-2844636-B1 | METHODS FOR THE TREATMENT OF PROLIFERATIVE DIABETIC RETINOPATHY | ACUCELA INC (US) | 2020-04-22 | — | — | EP | disclosed |
| US-9957224-B2 | Methods for the treatment of diabetic retinopathy and other ophthalmic diseases | ACUCELA INC (US) | 2018-05-01 | — | — | US | disclosed |
| US-9464033-B2 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-9464033-B2 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-9464033-B2 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20150329473-A1 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2015-11-19 | — | — | US | disclosed |
| US-20150329473-A1 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2015-11-19 | — | — | US | disclosed |
| US-8299307-B2 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120004269-A1 | Alkynyl Phenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ACUCELA INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004269-A1 | Alkynyl Phenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ACUCELA INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004269-A1 | Alkynyl Phenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | ACUCELA INC. (US) | 2012-01-05 | — | — | US | disclosed |
| EP-2076122-A2 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | Acucela, Inc. (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20090062353-A1 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA, INC. | 2009-03-05 | — | — | US | disclosed |
| US-20090062353-A1 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA, INC. | 2009-03-05 | — | — | US | disclosed |
| US-20090062353-A1 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA, INC. | 2009-03-05 | — | — | US | disclosed |
| WO-2009005794-A2 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009005794-A2 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10730825-B2 | Methods for the treatment of diabetic retinopathy and other ophthalmic diseases | ALDH1A2, ALDH1A3, RBP4 | GRM5 2947/4885KDM4E 4647/4885 |
| US-20090062353-A1 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | PDE6D, STARD3, PDE6C | GRM5 4439/4885KDM4E 2114/4885 |
| US-11795136-B2 | Methods for the treatment of diabetic retinopathy and other ophthalmic diseases | ALDH1A2, ALDH1A3, RBP4 | GRM5 2947/4885KDM4E 4647/4885 |
| US-20210171435-A1 | Methods for the Treatment of Diabetic Retinopathy and other Ophthalmic Diseases | ALDH1A2, ALDH1A3, RBP4 | GRM5 2947/4885KDM4E 4647/4885 |
| US-20120004269-A1 | Alkynyl Phenyl Derivative Compounds for Treating Ophthalmic Diseases and Disorders | PDE6D, STARD3, PDE6C | GRM5 4439/4885KDM4E 2114/4885 |
| US-20150329473-A1 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, STARD3, PDE6C | GRM5 4439/4885KDM4E 2114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.